Lipidomics Revealed Plasma Phospholipid Profile Differences between Deceased and Recovered COVID-19 Patients

Biomolecules. 2022 Oct 15;12(10):1488. doi: 10.3390/biom12101488.

Abstract

Thorough understanding of metabolic changes, including lipidome alteration, associated with the development of COVID-19 appears to be crucial, as new types of coronaviruses are still reported. In this study, we analyzed the differences in the plasma phospholipid profiles of the deceased COVID-19 patients, those who recovered and healthy people. Due to identified abnormalities in plasma phospholipid profiles, deceased patients were further divided into two subgroups (D1 and D2). Increased levels of phosphatidylethanolamines (PE), phosphatidylcholines (PC) and phosphatidylserines (PS) were found in the plasma of recovered patients and the majority of deceased patients (first subgroup D1) compared to the control group. However, abundances of all relevant PE, PC and PS species decreased dramatically in the plasma of the second subgroup (D2) of five deceased patients. These patients also had significantly decreased plasma COX-2 activity when compared to the control, in contrast to unchanged and increased COX-2 activity in the plasma of the other deceased patients and recovered patients, respectively. Moreover, these five deceased patients were characterized by abnormally low CRP levels and tremendous increase in LDH levels, which may be the result of other pathophysiological disorders, including disorders of the immune system, liver damage and haemolytic anemia. In addition, an observed trend to decrease the autoantibodies against oxidative modifications of low-density lipoprotein (oLAb) titer in all, especially in deceased patients, indicate systemic oxidative stress and altered immune system that may have prognostic value in COVID-19.

Keywords: COVID-19; SARS-CoV-2; lipidomics; low-density lipoprotein; phospholipids; plasma.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Autoantibodies
  • COVID-19*
  • Cyclooxygenase 2
  • Humans
  • Lipidomics
  • Lipoproteins, LDL
  • Phosphatidylcholines
  • Phosphatidylethanolamines / metabolism
  • Phosphatidylserines / metabolism
  • Phospholipids* / metabolism

Substances

  • Phospholipids
  • Phosphatidylethanolamines
  • Phosphatidylserines
  • Cyclooxygenase 2
  • Phosphatidylcholines
  • Lipoproteins, LDL
  • Autoantibodies

Grants and funding

This study was financed by the Medical University of Białystok, Poland.